Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avax Technologies has launched its M-Vax melanoma treatment in Switzerland through its Swiss distribution partner Pro Vaccine.
Subscribe to our email newsletter
Marketing of M-Vax started after recently receiving authorization from the Swiss Health authorities. The vaccine will be produced by Avax’s wholly owned subsidiary, Genopoietic, located in Lyon, France.
M-Vax is one of several autologous cell vaccines based on Avax’s proprietary AC vaccine technology. To date over 500 patients have been treated with the AC vaccine technology in three different cancer indications. In addition, the safety and efficacy of M-Vax has been evaluated in over 400 patients with stage III and IV melanoma.
The company anticipates initiating additional clinical studies in the US and France before the end of the year to evaluate the safety and efficacy of the AC Vaccine technology in patients with non-small cell lung cancer, metastatic ovarian cancer and metastatic colo-rectal cancer patients.
Richard Rainey, president of Avax said: “We are committed to expanding the company’s global presence in the field of cancer vaccines, and continue to pursue other international market opportunities, while we seek approval of our AC vaccine technology in the US.”